ARTICLE | Finance

More motivation from Medivation

Medivation gets second share boost with MDV3100 safety in prostate cancer

February 6, 2012 8:00 AM UTC

Medivation Inc. (NASDAQ:MDVN) reached a 52-week high on Wednesday when it gained $12.16 (22%) to $67.57 on detailed results of the Phase III AFFIRM trial of MDV3100 to treat chemotherapy-resistant metastatic castration-resistant prostate cancer (CRPC).

The updated data helped erase any lingering doubts about the oral androgen receptor antagonist and its ability to compete in metastatic CRPC with Zytiga abiraterone from Johnson & Johnson (NYSE:JNJ). Unlike Zytiga, MDV3100 does not need to be given in combination with the steroid prednisone...